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Abstract
Objectives—To determine diagnostic testing patterns after percutaneous coronary intervention
(PCI).
Background—Little is known about patterns of diagnostic testing after PCI in the U.S. or the
relationship of these patterns with clinical outcomes.
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Methods—We linked Centers for Medicare & Medicaid Services inpatient and outpatient claims
to the National Cardiovascular Data Registry® CathPCI Registry® data from 2005–2007. Hospital
quartiles of the cumulative incidence of diagnostic testing use within 12 and 24 months post-PCI
were compared for patient characteristics, repeat revascularization, acute myocardial infarction
(AMI), and death.
Results—A total of 247,052 patients underwent PCI at 656 institutions. Patient and site
characteristics were similar across testing use quartiles. There was a 9% and 20% higher adjusted
risk of repeat revascularization in Quartile 3 and Quartile 4 (highest testing rate), respectively,
when compared to Quartile 1 (lowest testing rate) (p=0.020 and <0.0001, respectively). The
adjusted risk for death or AMI did not differ among quartiles.
Conclusions—While patient characteristics were largely independent of rates of post-PCI
testing, higher testing rates was not associated with lower risks of myocardial infarction or death,
but repeat revascularization was significantly higher at these sites. Additional studies should
examine whether increased testing is a marker for improved quality of post-PCI care or simply
increased healthcare utilization.
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stress testing; diagnostic catheterization; site-level patterns; patient outcomes
Despite the utility of cardiac imaging technologies for guiding clinical decision making,
increased utilization of testing in recent decades has raised concerns regarding possible
over-use, particularly in light of rising overall U.S. health care costs (1). This increase in
cardiac imaging has occurred as the incidence of coronary disease has remained stable, if not
decreased slightly (2,3). Cardiac stress testing and diagnostic angiography are among the
most commonly performed diagnostic tests, and are often used after revascularization—
particularly percutaneous coronary intervention (PCI).
Previous studies have demonstrated significant regional variation in cardiac imaging and
cardiac catheterization use (4–7) that does not appear to be entirely due to differences in
patient characteristics. Cross-sectional and observational studies examining variation in
testing have demonstrated that greater diagnostic testing results in increased invasive
procedures and interventions (8,9). Nevertheless, it is unclear if these patterns represent
increased use or overuse from routine surveillance testing (5). Together, these concerns
prompted the American College of Cardiology Foundation (ACCF) to develop Appropriate
Use Criteria for imaging stress testing in hopes of decreasing variation, and to target
scenarios providing the most clinical benefit (10,11).
Prior studies have not examined the institutional variations in testing or the associated
clinical outcomes after PCI. To address these gaps, we assessed the relationship between
rates of diagnostic testing for coronary artery disease following PCI and the incidence of
repeat revascularization, acute myocardial infarction (AMI), and death in a national patient
cohort.
Methods
The Duke University Medical Center Institutional Review Board granted a waiver of
informed consent and authorization for this study, and the Duke Clinical Research Institute
conducted all analyses.
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The study population included all patients receiving PCI with stenting who were at least 65
years of age, were admitted and discharged between January 2004 and December 2008, and
were enrolled in the National Cardiovascular Data Registry® (NCDR) CathPCI Registry®.
The CathPCI Registry is a large, national, clinical registry of patients undergoing cardiac
catheterization or PCI. For each patient, the first PCI with stent procedure captured in the
CathPCI Registry was considered to be the index event and was treated as the initial unit of
analysis. There were a total of 672,617 eligible index events of which 67% linked to a single
record in the Centers for Medicare & Medicaid Services (CMS) inpatient claims data for
patients >65 years old using an established probabilistic matching methodology (12,13).
Index PCI events were matched to CMS claims data using three variables: sex, age, and date
of service for the PCI procedure. Matching to the CMS data allowed identification of
subsequent inpatient and outpatient claims. The patient was treated as the unit of analysis.
The linked cohort was restricted to patients receiving only stent type (either bare metal or
drug-eluting) allowing for comparisons by stent type. Multiple revascularization procedures
within a single encounter were considered a single revascularization event. Patients were
excluded if they did not have both Part A (inpatient hospital) and Part B (physician services
and outpatient hospital) Medicare during their index admission. Also, patients were
excluded who did not have physician claims for their index intervention or had a primary
payer besides Medicare (Figure 1a).
Study population
Since Version 3 of the CathPCI Registry data collection form was implemented nationwide
on January 1, 2005, we restricted our analysis to patients treated on or after this date;
similarly, since we had follow-up data through December 31, 2008, only patients treated
prior to December 31, 2007 were included to ensure a minimum one-year follow-up (Figure
1b). Patients who did not have fee-for-service Medicare coverage for the entire follow-up
period were censored once they ceased to have such coverage.
A 60-day blackout period after PCI was defined for each patient since diagnostic tests
during this early period may be performed for cardiac rehabilitation, staging of procedures,
or functional capacity assessments. Patients were excluded if they did not survive this
blackout period or did not retain both Part A and Part B Medicare coverage. Additionally,
patients receiving stress positron emission tomography, coronary computed tomography
angiography, or stress magnetic resonance imaging after the 60-day blackout period were
excluded, because they were rarely performed in this study cohort. Finally, we limited the
sample to those hospitals that performed at least 50 PCI procedures during analysis period to
eliminate hospitals with low procedural volumes.
Data definitions
The use of cardiac stress testing with and without imaging after coronary stent implantation
was assessed by examining testing patterns following the initial revascularization procedure
overall and stratified by type of test, which were identified by Current Procedural
Terminology (CPT) codes (see Appendix for codes). The type, number, and dates of any
cardiac testing or imaging procedure 60 days after the index coronary stent placement were
used to stratify patients based on type of first diagnostic test after stenting. Stress
electrocardiogram (ECG) and imaging procedures performed within one day of each other
were considered a single stress event.
The number and dates of repeat catheterizations and coronary revascularization (e.g., PCI or
coronary artery bypass grafting [CABG] surgery) following the first diagnostic test were
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identified using CPT and International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) codes. Lastly, acute myocardial infarction (AMI) was defined
according to ICD-9-CM coding (see Appendix for codes).
Statistical analysis
Patient and hospital baseline characteristics of patients undergoing an index
revascularization stent procedure were provided overall and by hospital quartiles of
cumulative incidence rate stress testing at 12 months post-PCI using descriptive statistics
(number of observations, mean, standard deviation, median, 25th and 75th percentiles,
minimum, and maximum) for numerical (or continuous) variables and with frequency and
percentage for categorical variables. Bivariate tests of association were based on either
Pearson chi-square tests for categorical variables or Kruskal-Wallis tests for continuous or
ordinal variables.
Time-to-first stress test occurring at least 60 days after the index revascularization episode
were calculated using cumulative incidence functions that accounted for administrative
censoring; death, AMI, and catheterization were considered competing risks. Cumulative
incidence rates at 12 months were calculated separately for each institution. Institutions were
categorized based on quartiles of cumulative incidence of stress testing. To examine trends
of institutional cumulative incidence rates at 12 months over calendar time, we estimated an
intraclass correlation from a linear random effects model with institution as a random effect.
Cause-specific Cox proportional hazards models were used to estimate hazard ratios
associated with risk of death first, AMI first, and revascularization first, with adjustment for
baseline variables that were selected a priori based on clinical expertise. A robust variance
estimator was used to account for the possible within-cluster correlation (14). We adjusted
for age, race, gender, body mass index (BMI), acute coronary syndrome (ACS) at time of
index PCI, peripheral vascular disease, history of congestive heart failure (CHF), diabetes,
hypertension, dyslipidemia, current smoking status, cerebrovascular disease, family history
of coronary artery disease before age 55, previous MI more than seven days before index
PCI, chronic lung disease, drug-eluting stent versus bare metal stent, glomerular filtration
rate <30 ml/min or receiving dialysis, previous PCI, previous CABG, current CHF status,
year of index PCI, hospital type (government, private and teaching, private and non-
teaching, versus university), average annual PCI volume, number of CMS-certified beds,
and region. In each model, patients were censored at the end of follow-up, or at 365 or 720
days. To describe whether clinical events rates (AMI, repeat revascularization, death)
differed by quartile of testing, we calculated 12-month and 720-day institutional event rates
per 100 person-years and calculated the median of the institutional event rates separately for
each quartile. To examine outcomes up to 365 and 720 days, we plotted the cumulative
incidence using the Kaplan-Meier method and tested for equality of survivor functions with
the log-rank test.
All statistical analyses were conducted using SAS version 9.2 or higher (SAS Institute Inc.,
Cary, NC) and Stata Statistical Software: Release 11 (StataCorp, College Station, TX). All
statistical tests were two-sided with a significance level of 0.05.
Results
The study population included 247,052 patients who underwent PCI with stenting between
2005–2007 at 656 hospitals (Figures 1a and 1b). Mean duration of follow-up was 756 days
(25th–75th percentile, 512–1047 days). Overall, 79,741 (32.3%) patients had a stress ECG,
stress echocardiography, or stress nuclear as the first test in the interval from 60–365 days
after coronary stenting, 18,455 (7.5%) patients had invasive diagnostic coronary
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angiography as the first test, and 148,856 (60.3%) patients had no testing in the 60–365 day
interval after coronary stenting.
Institutional quartiles of testing incidence
We examined the site-level 12-month cumulative incidence rate of stress testing used as the
first test within 60–365 days after PCI, with either stress testing or cardiac catheterization
used as the first test after PCI. The institutional 12-month cumulative incidence rates of any
stress testing varied from 8.6% to 66.0% (median 31.6%, 25th–75th percentile, 24.7%–
38.9%). The intraclass correlation of cumulative incidence of non-invasive testing between
sites over study years was 0.702 (95% CI: 0.668–0.735).
Patient and hospital characteristics
After sites were stratified into quartiles based on their 12-month testing cumulative
incidence during the study period, we compared baseline characteristics and demographics
of patients at the time of index PCI. This comparison was done first for quartiles of hospitals
based on rates of patients undergoing stress testing as the first test after PCI (Table).
Stress test first—Patient characteristics were largely similar across hospital quartiles for
cumulative incidence of testing. Compared to the lowest testing rate quartiles, patients
receiving PCI at the highest testing rate quartile were less likely to be Caucasian, or to have
BMI ≥30, previous CHF, or ACS at index presentation. There was some also variability of
site characteristics across the quartiles in use of drug-eluting stents, annual PCI volumes,
and geography, but there were no clear trends in these differences across quartiles.
Unadjusted outcomes—Clinical outcomes at least 60 days after index PCI and up to 12
months after index PCI were examined overall and by hospital testing quartile (Figure 2).
Overall, the incidence rates of repeat revascularization (CABG or PCI), AMI, or death
within 12 months were 4.1, 2.3, and 5.2, respectively, per 100 person-years.
Adjusted outcomes for patients after PCI
Among hospital quartiles of stress testing use as the first test after PCI, no statistical
difference in the cumulative incidence of death (p=0.187) or hospitalization for AMI
(p=0.51) at 12 months after PCI was found when the higher three quartiles were jointly
compared to the lowest quartile of testing (Quartile 1). In contrast, there was a highly
significant difference in the incidence of repeat revascularization at 12 months after PCI
(p<0.001). In pairwise comparisons, there were statistically significant 9% and 20%
increases in repeat revascularization among sites in Quartile 3 and Quartile 4, respectively,
compared to Quartile 1 (p=0.020 and <0.001, respectively; Figure 3).
When examining outcomes at least 60 days and up to 720 days after PCI, we found that the
cumulative incidence rate of death for the lowest tested quartile (Quartile 1) compared to the
other three quartiles was similar, although statistically significant (10.5%, 10.8%, 10.1% and
10.1%, respectively [p=0.011]). No significant clinical differences at 720 days were found
when comparing Quartile 1 to the other three quartiles for the cumulative incidence of
hospitalization for AMI (4.5%, 4.8%, 4.6%, 4.3% for Quartile 1–4, respectively [p=0.041]).
Finally, a significant difference in the rates of repeat revascularization was found across the
four groups with increasing rates of revascularization as testing quartile increased (13.8%,
13.8%, 14.7%, 15.4% for Quartiles 1–4, respectively; [p<0.001]). When examined by repeat
revascularization type (PCI or CABG), there was no difference in the use of CABG across
the 4 testing quartiles (1.93%, 1.92%, 2.04%, 1.94% for Quartiles 1–4, respectively; p =
0.567), whereas increased for PCI as testing quartile increased (12.3%, 12.3%, 13.2%,
14.0% for Quartiles 1–4, respectively; p<0.001) at 720 days.
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In this national cohort undergoing PCI, there was marked variation in the use of subsequent
cardiovascular testing that is not fully explained by differences in patient and hospital
characteristics. Furthermore, increased use of testing after PCI is associated with a clear
increase in repeat revascularization; however, the variation of testing and downstream
revascularization did not result in decreased AMI or mortality.
In the current study, we found significant variation in non-invasive stress testing after PCI
across Medicare fee-for-service sites with a range of 17% to 73% and a mean of 40% at 12
months. These rates parallel previous reports of cumulative incidence of 36% for either
stress echocardiography or stress nuclear testing at 12 months in a non-Medicare population
(5). Relative to previous reports in other PCI analyses, these rates are high, where less than
15% patients develop symptoms requiring reevaluation within 12 months post-PCI (15,16).
In our study, there were no significant differences in patient characteristics among sites
stratified by quartile of testing use demonstrating that increased patient risk was not
associated with increased testing use and vice versa. Specifically, patient characteristics,
such as diabetes or a history of silent ischemia (i.e., no chest pain prior to index PCI) or bare
metal stent use (versus drug-eluting stent), were not more common at sites with more
frequent testing. This finding is similar to our prior observations in non-Medicare patients
(5) suggesting significant opportunities exist to improve guidance on appropriate indications
for testing.
We used the naturally occurring variation in testing rates across institutions to explore
whether variation in the specified outcomes might be associated with different testing
intensities. In particular, the variation in testing rates may be interpreted as a surrogate for
the different post-PCI management strategies of ischemic symptom-driven testing (lower
rates of use) versus surveillance testing (higher rates of use). The lack of association
between stress testing use and clinical outcomes of death or AMI, suggests that the more
intensive testing use (implying a surveillance testing strategy) did not prevent or reduce
post-PCI events in the short- to medium-term. This lack of difference in death related to
testing use after PCI parallels findings from prior studies examining the association of
testing intensity and outcomes after AMI when controlling for patient characteristics (17).
Nevertheless, our data only infer the presence of different diagnostic strategies and the
associated outcomes.
In contrast to AMI and death, when examining the physician-guided outcome of repeat
revascularization, a significantly higher utilization (up to 37% more) was found among sites
that tested more frequently after PCI. Additionally, we found that the use of repeat
revascularization with CABG was constant across testing quartiles, but repeat PCI increased
with increased site testing. This clinical cascade mirrors previous studies demonstrating that
increased imaging use leads to increased invasive procedures and interventions (8,9). To our
knowledge, our findings are the first to use observational data to demonstrate that increased
testing after PCI is not associated with lower rates of death or AMI, and is consistent with
multiple randomized clinical trials that have found no reduction in events after PCI
(18,19,20).
Despite the large number of sites and patient data available, our study had several
limitations. First, data are limited to fee-for-service Medicare and CathPCI Registry patients.
As a result, data on symptoms, clinical presentation, and findings at the time of retesting are
unavailable and may differ between groups. It is unknown if higher rates of testing and
revascularization result in better symptomatic outcomes, which are also important indicators
to patients. Second, we have limited follow-up for patients and could not observe longer-
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term (greater than 24 months) outcomes. Despite similar patients across the utilization
quartiles, we could not exclude clinicians who may have correctly identified higher clinical
risk and may have acted appropriately upon abnormal test results by repeat coronary
intervention. However, given the very low rates of subsequent repeat revascularization in
this population, it is unlikely that repeat revascularization would be a significant driver of
AMI reduction or death in our population. Also, follow-up events following PCI relied on
ICD-9 codes as opposed to clinically adjudicated events which could understate the
occurrence of events in our analysis cohort. Finally, we do not have information regarding
other valid reasons to test, such as patient or provider preferences or need for patient
reassurance.
In conclusion, our findings suggest that linking clinically rich patient registries with
administrative data can create a platform to examine use of testing after PCI. It is unknown
whether increased testing after PCI with increased subsequent repeat revascularization is a
marker of higher quality post-PCI care, or simply an indication of increased health care
utilization. Future studies should examine the indications for and results of post-PCI testing
to further assess their use for patients to better understand the associated clinical outcomes.
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Figure 1. Population Description
This figure displays a description of: (a) the linked dataset population; and (b) the study
population.
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Figure 2. Observed 12-month Median Outcomes per 100 Person-Years by Hospital Quartile
This figure displays the observed 12-month median outcomes per 100 person-years by
hospital quartile of stress testing 60–365 days after index PCI.
Shah et al. Page 11













Figure 3. Adjusted Outcomes by Non-invasive Testing Quartiles
This figure displays the adjusted outcomes of non-invasive testing quartiles for death,
myocardial infarction, and revascularization.
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